We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bruker Debuts Fourier 80 Multinuclear Benchtop FT-NMR: Stock to Gain?
Read MoreHide Full Article
Bruker Corporation (BRKR - Free Report) has introduced an innovative Fourier 80 multinuclear benchtop FT-Nuclear Magnetic Resonance (NMR) spectrometer, known as the ‘Multi-Talent’ configuration. Unveiled at the Joint ENC-ISMAR Conference 2025, the system’s unique, next-generation capabilities meet the evolving needs of academic researchers and industry scientists with significantly enhanced versatility in benchtop FT-NMR multinuclear analysis.
The latest development from Bruker marks a major advancement in permanent magnet-based FT-NMR technology and is expected to boost the performance of its BioSpin Group.
BRKR Stock’s Likely Trend Following the News
Since the announcement on April 7, Bruker shares have dropped 1.6%, closing at $38.07 in yesterday’s session. On a promising note, the company already has successfully installed a dozen Fourier 80 multinuclear systems in customer labs, and expects that the latest Fourier 80 multinuclear benchtop FT-NMR system may become the new de facto standard in benchtop multinuclear NMR spectroscopy. Accordingly, we anticipate this to boost the market sentiment toward BRKR stock.
Bruker has a market capitalization of $6.25 billion. The Zacks Consensus Estimate for the company’s 2025 earnings per share (EPS) indicates an increase of 11.6%. In the trailing four quarters, it delivered an earnings beat of 3.7%, on average.
Significance of Bruker’s New Benchtop FT-NMR
The Fourier 80 ‘Multi-Talent’ system measures or decouples1H, and in addition, can select one of 15 different X-nuclei to be either observed in X{1H} experiments or selected X-nuclei can be decoupled for proton observation in 1H{X} experiments. This enables many types of X-nucleus observations, various 2D experiments and also the exquisitely sensitive inverse 1H observation methods for 13C, 19F or 15N experiments.
Image Source: Zacks Investment Research
Similarly, the Fourier 80 ‘Multi-Talent’ can observe 19F{1H} with proton decoupling for the simplification of 19F spectra, a capability of high interest to pharmaceutical customers studying fluorinated drug candidates. For battery research, the Fourier 80 ‘Multi-Talent’ enables nuclei observations from Li-brine mining, like 7Li, 23Na and 11B for the formulation of battery electrolytes. Novel electrochemical systems can be explored to advance next-generation battery technologies. These unprecedented benchtop capabilities are selectable via software, eliminating the need for NMR probe tuning and matching.
The ‘Multi-Talent’ uses standard 5 mm NMR samples and includes gradient spectroscopy with options for adjustable sample temperature or sample changer automation. The user-friendly Fourier 80 interface ensures that novice and experienced users can navigate through measurements effortlessly, streamlining complex tasks and enhancing productivity.
Bruker’s Industry Prospects Favorable
Per a research report, the benchtop NMR spectrometer market was valued at $350 million in 2024 and is expected to grow at a compound annual rate of 5.5% through 2033. More organizations are turning to NMR technology to improve their workflows and minimize waste, enhancing their overall efficiency. The trend has gained more traction with the increasing R&D activities, particularly in the pharmaceutical and biotechnology sectors.
Other Developments in Bruker
This month, Bruker announced the first customer installation of its groundbreaking dissolution Dynamic Nuclear Polarization (d-DNP) Polarizer. The novel Polarizer enables scientists to conduct previously impossible experiments in chemical or metabolic analysis in NMR and preclinical MRI. Bruker provides a faster d-DNP approach using cross-polarization of 1H and 13C, which offers 5-10x faster polarization compared to traditional d-DNP of 13C.
BRKR Stock Price Performance
In the past three months, Bruker shares have declined 39.5% compared with the industry’s 35% fall.
Estimates for Veracyte’s 2025 EPS have jumped 6.9% in the past 30 days. Shares of the company have risen 49.5% in the past year against the industry’s 11.3% fall. Its earnings yield of 3.8% compares to the industry’s -3.6% yield. VCYT’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 515.9%.
Insulet shares have rallied 43.5% in the past year. The company has an estimated long-term earnings growth rate of 25.9% compared to the industry’s 16.5% growth. PODD’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 27.5%. In the last reported quarter, it posted an earnings surprise of 9.5%.
Estimates for Abbott’s 2025 EPS have remained constant at $5.15 in the past 30 days. Shares of the company have jumped 14.1% in the past year compared to the industry’s 1.5% growth. It has an earnings yield of 4.1% compared to the industry’s flat yield. ABT’s earnings surpassed estimates in three of the trailing four quarters and matched in one, the average surprise being 1.6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bruker Debuts Fourier 80 Multinuclear Benchtop FT-NMR: Stock to Gain?
Bruker Corporation (BRKR - Free Report) has introduced an innovative Fourier 80 multinuclear benchtop FT-Nuclear Magnetic Resonance (NMR) spectrometer, known as the ‘Multi-Talent’ configuration. Unveiled at the Joint ENC-ISMAR Conference 2025, the system’s unique, next-generation capabilities meet the evolving needs of academic researchers and industry scientists with significantly enhanced versatility in benchtop FT-NMR multinuclear analysis.
The latest development from Bruker marks a major advancement in permanent magnet-based FT-NMR technology and is expected to boost the performance of its BioSpin Group.
BRKR Stock’s Likely Trend Following the News
Since the announcement on April 7, Bruker shares have dropped 1.6%, closing at $38.07 in yesterday’s session. On a promising note, the company already has successfully installed a dozen Fourier 80 multinuclear systems in customer labs, and expects that the latest Fourier 80 multinuclear benchtop FT-NMR system may become the new de facto standard in benchtop multinuclear NMR spectroscopy. Accordingly, we anticipate this to boost the market sentiment toward BRKR stock.
Bruker has a market capitalization of $6.25 billion. The Zacks Consensus Estimate for the company’s 2025 earnings per share (EPS) indicates an increase of 11.6%. In the trailing four quarters, it delivered an earnings beat of 3.7%, on average.
Significance of Bruker’s New Benchtop FT-NMR
The Fourier 80 ‘Multi-Talent’ system measures or decouples1H, and in addition, can select one of 15 different X-nuclei to be either observed in X{1H} experiments or selected X-nuclei can be decoupled for proton observation in 1H{X} experiments. This enables many types of X-nucleus observations, various 2D experiments and also the exquisitely sensitive inverse 1H observation methods for 13C, 19F or 15N experiments.
Image Source: Zacks Investment Research
Similarly, the Fourier 80 ‘Multi-Talent’ can observe 19F{1H} with proton decoupling for the simplification of 19F spectra, a capability of high interest to pharmaceutical customers studying fluorinated drug candidates. For battery research, the Fourier 80 ‘Multi-Talent’ enables nuclei observations from Li-brine mining, like 7Li, 23Na and 11B for the formulation of battery electrolytes. Novel electrochemical systems can be explored to advance next-generation battery technologies. These unprecedented benchtop capabilities are selectable via software, eliminating the need for NMR probe tuning and matching.
The ‘Multi-Talent’ uses standard 5 mm NMR samples and includes gradient spectroscopy with options for adjustable sample temperature or sample changer automation. The user-friendly Fourier 80 interface ensures that novice and experienced users can navigate through measurements effortlessly, streamlining complex tasks and enhancing productivity.
Bruker’s Industry Prospects Favorable
Per a research report, the benchtop NMR spectrometer market was valued at $350 million in 2024 and is expected to grow at a compound annual rate of 5.5% through 2033. More organizations are turning to NMR technology to improve their workflows and minimize waste, enhancing their overall efficiency. The trend has gained more traction with the increasing R&D activities, particularly in the pharmaceutical and biotechnology sectors.
Other Developments in Bruker
This month, Bruker announced the first customer installation of its groundbreaking dissolution Dynamic Nuclear Polarization (d-DNP) Polarizer. The novel Polarizer enables scientists to conduct previously impossible experiments in chemical or metabolic analysis in NMR and preclinical MRI. Bruker provides a faster d-DNP approach using cross-polarization of 1H and 13C, which offers 5-10x faster polarization compared to traditional d-DNP of 13C.
BRKR Stock Price Performance
In the past three months, Bruker shares have declined 39.5% compared with the industry’s 35% fall.
BRKR’s Zacks Rank and Key Picks
Bruker currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space include Veracyte (VCYT - Free Report) , Insulet (PODD - Free Report) and Abbott (ABT - Free Report) . Each of these carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Estimates for Veracyte’s 2025 EPS have jumped 6.9% in the past 30 days. Shares of the company have risen 49.5% in the past year against the industry’s 11.3% fall. Its earnings yield of 3.8% compares to the industry’s -3.6% yield. VCYT’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 515.9%.
Insulet shares have rallied 43.5% in the past year. The company has an estimated long-term earnings growth rate of 25.9% compared to the industry’s 16.5% growth. PODD’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 27.5%. In the last reported quarter, it posted an earnings surprise of 9.5%.
Estimates for Abbott’s 2025 EPS have remained constant at $5.15 in the past 30 days. Shares of the company have jumped 14.1% in the past year compared to the industry’s 1.5% growth. It has an earnings yield of 4.1% compared to the industry’s flat yield. ABT’s earnings surpassed estimates in three of the trailing four quarters and matched in one, the average surprise being 1.6%.